NASM North American Scientific (MM)

North American Scientific (NASDAQ:NASM) announced today that it has appointed Robin Gibbs to the position of Vice President of Marketing. Ms. Gibbs, formerly a Vice President of Global Franchise Management for Edwards Lifesciences, will lead the marketing team for the company�s growing Radiation Sources division, including the new ClearPath HDR and ClearPath CR devices which allow customized local radiation dosing for the breast cancer patient. Ms. Gibbs will report directly to John Rush, President and CEO of North American Scientific. �Robin brings 30 years of commercial experience with clinical diagnostics and medical devices to our organization,� said Mr. Rush. �Her global strategic marketing skills will add the appropriate level of expertise to the senior team as we develop and implement strategies to expand our business worldwide and prepare for launch of our new ClearPath products for the Breast Cancer market.� Ms. Gibbs joins North American Scientific from MedX3, LLC, a marketing and business development firm where she held a principal position. In her career, she has held positions with significant responsibility including roles as Vice President of Global Franchise Management, Vice President of Global Marketing Cardiovascular Surgery, Vice president of Global Marketing Heart Valve Therapy, and Director of National Accounts. Ms. Gibbs began her career in sales and sales management positions with American Hospital Supply and Baxter Healthcare. About North American Scientific North American Scientific is a medical device company focused on developing products which deliver local controlled radiation therapy for cancer. Its innovative products allow patients to be treated effectively with a shortened course of treatment and reduced side effects. Current products include the Prospera� Iodine and Palladium seeds and SurTRAK� needles and strands used primarily in the treatment of prostate cancer. Additionally, the Company has been gaining clinical experience with its ClearPath� multi-channel catheter device for local radiation delivery in the breast cancer patient. The ClearPath family of products are the only such devices approved for both high dose and continuous release, or low dose, local radiation treatments for breast cancer. The devices are designed to provide flexible, precise dose customization and unparalleled patient comfort in a shortened, effective course of treatment. Please visit www.nasmedical.com for more information.